GlassScriptPhysician profile
Stephanie Danielle Sisson
NPI 1235651779
$4,606.25
in general payments reported to CMS, 2019-2025
36 companies · $799 in 2025
The $799 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $861 · 2022: $876 · 2023: $1,364 · 2024: $706 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,869.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,619.50 | 2021-2025 | |
| Amgen INC. | $329.72 | 2021-2023 | Evenity, Prolia |
| Pfizer INC. | $281.04 | 2021-2025 | |
| Exact Sciences Corporation | $278.22 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $272.70 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $268.90 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $259.81 | 2021-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $231.65 | 2021-2023 | |
| Axsome Therapeutics, INC. | $106.22 | 2023-2025 | Auvelity, Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $92.83 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $82.67 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $73.07 | 2022-2025 | Evusheld |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.71 | 2024-2025 | Caplyta |
| Shield Therapeutics INC | $63.91 | 2022-2023 | Accrufer |
| Glaxosmithkline, LLC. | $58.02 | 2021-2023 | Trelegy Ellipta |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $49.57 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $43.03 | 2022-2023 | Quviviq |
| Tris Pharma INC | $42.61 | 2022-2023 | Dyanavel Xr |
| Dexcom, INC. | $38.55 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $38.46 | 2023 | |
| Cranial Technologies, INC | $30.00 | 2024-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $29.21 | 2023 | Jornay Pm |
| Biogen, INC. | $26.57 | 2025 | Zurzuvae |
| Esperion Therapeutics, INC. | $24.51 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.75 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.74 | 2025 | Voquezna |
| Lundbeck LLC | $18.61 | 2023 | Rexulti |
| Astellas Pharma US INC | $18.52 | 2023 | Veozah |
| Biohaven Pharmaceuticals, INC. | $16.96 | 2021 | |
| Tolmar, INC. | $16.51 | 2025 | Jatenzo |
| Currax Pharmaceuticals LLC | $15.38 | 2023 | Contrave |
| Genentech USA, INC. | $14.62 | 2021 | |
| Merck Sharp & Dohme LLC | $14.45 | 2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $13.67 | 2022 | |
| Inspire Medical Systems, INC. | $13.64 | 2025 | Inspire |
| Supernus Pharmaceuticals, INC. | $12.92 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Sisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.